Amgen Q1 2026 revenue $8.6B (+6% YoY), Non-GAAP EPS $5.15 (+5% YoY)

AMGEN INC

2026-Q1 EPS reported $3.34 revenue$8,618,000,000

Total revenue $8.6B (+6% YoY); product sales grew 4% driven by 9% volume growth.
GAAP EPS $3.34 (+4% YoY); Non-GAAP EPS $5.15 (+5% YoY).
GAAP operating income $2.7B, margin 32.4% (up 17.4pp); Non-GAAP operating income $3.7B, margin 45.3% (down 0.4pp).
Free cash flow $1.5B in Q1 2026 vs $1.0B in Q1 2025.
16 products achieved double-digit sales growth in Q1 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AMGEN INC reported the three months ended March 31, 2026 results: revenue $8.6 billion, EPS $3.34 (GAAP), $5.15 (Non-GAAP).

Period: the three months ended March 31, 2026
Revenue: $8.6 billion
EPS: $3.34 (GAAP), $5.15 (Non-GAAP)
Result: reported results

Exact text from the filing

deliver attractive long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: • For the first quarter, total revenues increased 6% to $8.6 billion in comparison to the first quarter of 2025. ◦ Produ ct sales grew 4% , driven by 9% volume growth, partially offset by 2% lower net selling price and 2% from lower inventory

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

AMGEN INC filing history →

Source: SEC EDGAR

accession 0000318154-26-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.